🧬✨ Breaking Barriers in Cancer Immunotherapy: Dual Targeting PD-L1 and Sialic Acid with a Nanobody-Enzyme Fusion
In the rapidly evolving world of cancer research, scientists are uncovering new ways to outsmart tumors that evade immune attacks. One groundbreaking discovery is the role of aberrant sialylated glycosylation — a sugar-coated immune suppression mechanism within the tumor microenvironment 🍬🧫. This hidden pathway acts as a glycoimmune checkpoint, silencing the body’s natural defenses and making cancer tougher to defeat.
💡 A New Hope in Glycoimmunotherapy
Current immunotherapies, though transformative, often struggle with tumor resistance and immune escape. Researchers have now identified a fascinating link between PD-L1 expression (a well-known immune inhibitor) and sialyltransferase enzymes in colorectal cancer tissues. These two culprits work hand-in-hand to shield tumors — but what if we could break their alliance? 🧩🔬 The Innovation: Nb16-Sia Fusion Protein
In a remarkable scientific leap, the team engineered a novel nanobody-enzyme fusion protein named Nb16-Sia, combining an anti-PD-L1 nanobody with a powerful sialidase enzyme discovered from human oral symbiotic bacteria 🦠. This fusion protein is designed to simultaneously target PD-L1 and remove sialic acid residues, dismantling cancer’s dual-layered defense system.🐁 From Bench to Breakthrough: Tumor Model Success
In experimental colon tumor models, Nb16-Sia outperformed conventional monotherapies and even their combinations. It didn’t just shrink tumors — it reprogrammed the immune landscape, flipping tumor-promoting M2 macrophages into anti-tumor M1 warriors ⚔️ via the C-type lectin pathway.🌿 Rewriting the Tumor Microenvironment
By restoring immune balance and enhancing macrophage-driven responses, Nb16-Sia opens a new chapter in cancer treatment — one where precision, synergy, and biological insight converge. This elegant design bridges glycoimmunology and nanobody technology, showcasing a powerful approach to overcome immune suppression at its molecular roots.🚀 Future Vision
Nb16-Sia represents more than a therapeutic innovation — it symbolizes a shift toward intelligent, multi-functional immunotherapies that adapt to the tumor’s complexity. As the research advances, this strategy could redefine how we treat cancers resistant to current checkpoint inhibitors.Scientific World Research Awards🏆
Visit our page : https://scientificworld.net/
Nominations page📃 : https://scientificworld.net/award-nomination/?ecategory=Awards&rcategory=Awardee
Get Connects Here:
==================
Youtube: https://www.youtube.com/@Scientificresearch-04
Instagram : https://www.instagram.com/swr_awards/
Blogger :https://www.blogger.com/blog/posts/8295489504259175195?hl=en&tab=jj
Twitter :https://x.com/SWR_Awards
What'sApp: https://whatsapp.com/channel/0029Vb5WOsUH5JLpZ1w0RD2M
No comments:
Post a Comment